China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.
Excellent balance sheet average dividend payer.
Share Price & News
How has China Shineway Pharmaceutical Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2877 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 2877 underperformed the Hong Kong Pharmaceuticals industry which returned 23.5% over the past year.
Return vs Market: 2877 underperformed the Hong Kong Market which returned 6.6% over the past year.
Price Volatility Vs. Market
How volatile is China Shineway Pharmaceutical Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StKey Things To Watch Out For If You Are After China Shineway Pharmaceutical Group Limited's (HKG:2877) 6.9% Dividend
1 month ago | Simply Wall StChina Shineway Pharmaceutical Group Limited (HKG:2877) Might Not Be As Mispriced As It Looks
1 month ago | Simply Wall StA Look At The Intrinsic Value Of China Shineway Pharmaceutical Group Limited (HKG:2877)
Is China Shineway Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 2877 (HK$5.41) is trading above our estimate of fair value (HK$4.44)
Significantly Below Fair Value: 2877 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 2877 is good value based on its PE Ratio (7.5x) compared to the HK Pharmaceuticals industry average (11x).
PE vs Market: 2877 is good value based on its PE Ratio (7.5x) compared to the Hong Kong market (10.3x).
Price to Earnings Growth Ratio
PEG Ratio: 2877 is poor value based on its PEG Ratio (1.3x)
Price to Book Ratio
PB vs Industry: 2877 is good value based on its PB Ratio (0.6x) compared to the HK Pharmaceuticals industry average (1.2x).
How is China Shineway Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2877's forecast earnings growth (5.6% per year) is above the savings rate (1.6%).
Earnings vs Market: 2877's earnings (5.6% per year) are forecast to grow slower than the Hong Kong market (18.7% per year).
High Growth Earnings: 2877's earnings are forecast to grow, but not significantly.
Revenue vs Market: 2877's revenue (5.5% per year) is forecast to grow slower than the Hong Kong market (11.4% per year).
High Growth Revenue: 2877's revenue (5.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2877's Return on Equity is forecast to be low in 3 years time (9.3%).
How has China Shineway Pharmaceutical Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2877 has high quality earnings.
Growing Profit Margin: 2877's current net profit margins (18.6%) are lower than last year (19.7%).
Past Earnings Growth Analysis
Earnings Trend: 2877's earnings have declined by 7.3% per year over the past 5 years.
Accelerating Growth: 2877's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 2877 had negative earnings growth (-0.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (0.4%).
Return on Equity
High ROE: 2877's Return on Equity (8.7%) is considered low.
How is China Shineway Pharmaceutical Group's financial position?
Financial Position Analysis
Short Term Liabilities: 2877's short term assets (CN¥5.2B) exceed its short term liabilities (CN¥1.2B).
Long Term Liabilities: 2877's short term assets (CN¥5.2B) exceed its long term liabilities (CN¥176.4M).
Debt to Equity History and Analysis
Debt Level: 2877's debt to equity ratio (6.9%) is considered satisfactory.
Reducing Debt: 2877's debt to equity ratio has increased from 4% to 6.9% over the past 5 years.
Debt Coverage: 2877's debt is well covered by operating cash flow (92.4%).
Interest Coverage: 2877 earns more interest than it pays, so coverage of interest payments is not a concern.
What is China Shineway Pharmaceutical Group current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 2877's dividend (6.6%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.35%).
High Dividend: 2877's dividend (6.6%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.76%).
Stability and Growth of Payments
Stable Dividend: 2877's dividend payments have been volatile in the past 10 years.
Growing Dividend: 2877's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (35.7%), 2877's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 2877's dividends in 3 years are forecast to be well covered by earnings (24.8% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
China Shineway Pharmaceutical Group has no CEO, or we have no data on them.
|Co-Founder & Executive Chairman||no data||CN¥4.68m||71.79% |
|Co-Founder & Executive Director||16.08yrs||CN¥2.70m||0.071% |
|Executive Director||16.08yrs||CN¥1.21m||0.13% |
|Executive Director||5.67yrs||CN¥1.81m||0.037% |
|Independent Non Executive Director||14.08yrs||CN¥140.00k||no data|
|Independent Non-Executive Director||1.58yrs||CN¥140.00k||no data|
|Independent Non-Executive Director||3.17yrs||CN¥140.00k||no data|
Experienced Board: 2877's board of directors are considered experienced (9.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
China Shineway Pharmaceutical Group Limited's company bio, employee growth, exchange listings and data sources
- Name: China Shineway Pharmaceutical Group Limited
- Ticker: 2877
- Exchange: SEHK
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$4.120b
- Shares outstanding: 761.63m
- Website: https://www.shineway.com
Number of Employees
- China Shineway Pharmaceutical Group Limited
- Luan Cheng
- Hebei Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|2877||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||Dec 2004|
|C1S||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 2004|
|2877||SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)||Yes||Ordinary Shares||HK||HKD||Dec 2004|
|2877||SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)||Yes||Ordinary Shares||HK||HKD||Dec 2004|
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong K ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/14 19:13|
|End of Day Share Price||2020/08/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.